Research Paper Volume 13, Issue 6 pp 8665—8687

MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling

EMP1 and miR-95-3p directly interact. (A) In silico prediction through the miRanda database demonstrated the presence of a binding site of miR-95-3p on EMP1 sequence. (B) Results from dual luciferase activity validate direct interaction between miR-95-3p and EMP1. (C) QRT-PCR results indicate EMP1 is lowly expressed in DDP-resistant GC tissues. (D) QRT-PCR suggests that EMP1 is lowly expressed in GC tissues compared to normal adjacent tissues. (E, F) QRT-PCR and western blot assay suggest that EMP1 is down-regulated in DDP-resistant SGC7901 cell line. **p

Figure 5. EMP1 and miR-95-3p directly interact. (A) In silico prediction through the miRanda database demonstrated the presence of a binding site of miR-95-3p on EMP1 sequence. (B) Results from dual luciferase activity validate direct interaction between miR-95-3p and EMP1. (C) QRT-PCR results indicate EMP1 is lowly expressed in DDP-resistant GC tissues. (D) QRT-PCR suggests that EMP1 is lowly expressed in GC tissues compared to normal adjacent tissues. (E, F) QRT-PCR and western blot assay suggest that EMP1 is down-regulated in DDP-resistant SGC7901 cell line. **p<0.01 compared to parental SGC7901.